0:16 - Introduction
0:45 - What was discussed?
2:40 - Joined by Dr. Jellinger
3:54 - Key Highlights from “Beyond LDL-C”
18:20 - Role of New Agents
21:00 - DCRM Multispecialty Practice Recommendations
35:00 - What is coming next?
37:55 - Conclusion
Both the treatment and the actual disease of diabetes does not exist in a vacuum - in fact, it may require a multispecialty and multidisciplinary approach for an effective therapeutic result.
Earlier this month, at the World Congress Insulin Resistance Diabetes and Cardiovascular Disease meeting, new guidelines were introduced to help bridge this gap in care.
They were entitled the DCRM Multispecialty Practice Recommendations for the Management of Diabetes, Cardiorenal, and Metabolic Diseases and recently published in the Journal of Diabetes and its Complications.
The document aimed to exist as a reference for specialists who can refer to particular sections in other specialties to see how the condition is being treated there, such as LDL, hypertension, or cardiovascular disease.
In this episode of DocTalk, Paul S. Jellinger, MD, Professor of Clinical Medicine on the voluntary faculty at the University of Miami and Private Practitioner, Endocrinology and Diabetes at the Center for Diabetes and Endocrine Care joined to discuss his role in the creation of the DCRM.
Particularly, he highlighted the information and insights in the Lipid section in the DCRM and what the document represents overall going forward.
At the same meeting, Jellinger chaired a session at the WCIRDC Meeting entitled “Beyond LDL-C: The Role of Dyslipidemia and ASCVD.”
He discussed and summarized the talks provided at the session, including introducing new concepts in therapy, getting LDL back to goal, combination therapies, and of course, the talk’s title, beyond LDL. Lastly, Jellinger explored what might come next for the field in 2022.
We hope you enjoy today's episode.